802 related articles for article (PubMed ID: 16737934)
1. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.
Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS
Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934
[TBL] [Abstract][Full Text] [Related]
2. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
3. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells.
Gaddy J; Broxmeyer HE
Cell Immunol; 1997 Sep; 180(2):132-42. PubMed ID: 9341743
[TBL] [Abstract][Full Text] [Related]
4. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.
Franceschetti M; Pievani A; Borleri G; Vago L; Fleischhauer K; Golay J; Introna M
Exp Hematol; 2009 May; 37(5):616-628.e2. PubMed ID: 19375652
[TBL] [Abstract][Full Text] [Related]
5. Effect of cyclosporin A on interleukin-15-activated umbilical cord blood natural killer cell function.
Lin SJ; Kuo ML
Cytotherapy; 2008; 10(4):397-405. PubMed ID: 18574772
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo expansion of natural killer cells for clinical applications.
Klingemann HG; Martinson J
Cytotherapy; 2004; 6(1):15-22. PubMed ID: 14985163
[TBL] [Abstract][Full Text] [Related]
7. Increased number of CD16(+)CD56(dim) NK cells in peripheral blood mononuclear cells after allogeneic cord blood transplantation.
Tanaka J; Sugita J; Asanuma S; Arita K; Shono Y; Kikutchi M; Shiratori S; Wakasa K; Yasumoto A; Shigematu A; Kondo T; Kobayashi T; Asaka M; Imamura M
Hum Immunol; 2009 Sep; 70(9):701-5. PubMed ID: 19524005
[TBL] [Abstract][Full Text] [Related]
8. IL-2-activated cord blood mononuclear cells.
Derzic S; Slone V; Sender L
Cytotherapy; 2005; 7(5):408-16. PubMed ID: 16236630
[TBL] [Abstract][Full Text] [Related]
9. Participation of the CD94 receptor complex in costimulation of human natural killer cells.
Voss SD; Daley J; Ritz J; Robertson MJ
J Immunol; 1998 Feb; 160(4):1618-26. PubMed ID: 9469418
[TBL] [Abstract][Full Text] [Related]
10. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.
Lu PH; Negrin RS
J Immunol; 1994 Aug; 153(4):1687-96. PubMed ID: 7519209
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic and functional heterogeneity of natural killer cells from umbilical cord blood mononuclear cells.
Fan YY; Yang BY; Wu CY
Immunol Invest; 2008; 37(1):79-96. PubMed ID: 18214801
[TBL] [Abstract][Full Text] [Related]
12. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
13. CD56brightCD16+ NK cells: a functional intermediate stage of NK cell differentiation.
Béziat V; Duffy D; Quoc SN; Le Garff-Tavernier M; Decocq J; Combadière B; Debré P; Vieillard V
J Immunol; 2011 Jun; 186(12):6753-61. PubMed ID: 21555534
[TBL] [Abstract][Full Text] [Related]
14. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
15. Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells.
Takahashi E; Kuranaga N; Satoh K; Habu Y; Shinomiya N; Asano T; Seki S; Hayakawa M
Scand J Immunol; 2007 Feb; 65(2):126-38. PubMed ID: 17257217
[TBL] [Abstract][Full Text] [Related]
16. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
[TBL] [Abstract][Full Text] [Related]
17. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.
Boissel L; Tuncer HH; Betancur M; Wolfberg A; Klingemann H
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1031-1038. PubMed ID: 18721766
[TBL] [Abstract][Full Text] [Related]
18. Expansion of natural killer cell receptor (CD94/NKG2A)-expressing cytolytic CD8 T cells and CD4+CD25+ regulatory T cells from the same cord blood unit.
Tanaka J; Sugita J; Kato N; Toubai T; Ibata M; Shono Y; Ota S; Kondo T; Kobayashi T; Kobayashi M; Asaka M; Imamura M
Exp Hematol; 2007 Oct; 35(10):1562-6. PubMed ID: 17681668
[TBL] [Abstract][Full Text] [Related]
19. Selective expansion and engraftment of human CD16+ NK cells in NOD/SCID mice.
Harada H; Suzu S; Ito T; Okada S
Eur J Immunol; 2005 Dec; 35(12):3599-609. PubMed ID: 16304638
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children.
Koehl U; Esser R; Zimmermann S; Tonn T; Kotchetkov R; Bartling T; Sörensen J; Grüttner HP; Bader P; Seifried E; Martin H; Lang P; Passweg JR; Klingebiel T; Schwabe D
Klin Padiatr; 2005; 217(6):345-50. PubMed ID: 16307421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
